Home|Journals|Articles by Year

Directory for Medical Articles
 

Research Article

JCDR. 2021; 12(3): 1056-1063


Anticitrullinated HSP90a In Rheumatoid Arthritis With Interstitial Lung Diseases

Esraa F.Abdallah, Mona H. Nasr, Moustafa A. Abdel-Wahab, Nezar R.Tawfike, Amany A. Bekhit, Ayman F. Darwish.


Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease that mostly affects the synovial joints. The arthritis is usually symmetrical, and it causes joint deterioration by eroding cartilage and bone. RA can also cause a variety of extra-articular symptoms (Esposito A, et al., 2019). While cardiac complications account for the majority of RA-related deaths, pulmonary involvement also plays a significant role in morbidity and mortality, accounting for about 10%–20% of all deaths (Esposito A, et al., 2019).

The parenchyma, pleura, airways, or vasculature can all be involved in pulmonary presentation, but parenchymal involvement from ILD is the most prevalent. Pulmonary involvement may occur before the development of articular symptoms in up to 20% of individuals (Esposito A, et al., 2019).

Autoantibodies in the blood have been linked to the development of RA-ILD. Smoking raises the risk through causing the development of antibodies as well as raising the citrullination of lung proteins, which increases their affinity for antibodies. (Shaw M, et al., 2015).

Anticyclic citrullinated protein antibodies (90 IU/ml) and high titers of rheumatoid factor (100 IU/ml) are indicators linked to an increased risk of developing RA-ILD (Zhu J, et al., 2014). Hsp90, a kind of antiicitrullinated protein antibody, shows a specificity of more than 95% for RA-ILD (Harlow L, et al., 2013).






Full-text options


Share this Article



Online Article Submission
• ejmanager.com







eJManager.com
Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.